Amgen's bone drug denosumab beats Zometa in Phase III trial
This article was originally published in Scrip
Executive Summary
Amgen's next big drug hope, denosumab, was more effective than Novartis's Zometa (zoledronic acid) in a Phase III trial in breast cancer patients with bone metastases in delaying the time to the first skeletal related event (SRE; fracture, radiation to bone, surgery to bone or spinal cord compression), preliminary results show.